OBJECTIVE: Long intergenic non-protein coding RNA 518 (LINC00518) was reported to be implicated and aberrantly expressed in multiple cancers. However, the pathogenic implications of LINC00518 in cervical cancer (CC) are still unclear. In this study, we focused on LINC00518 and investigated its expression pattern, clinical significance, and biological function in CC.
PATIENTS AND METHODS: The expression levels of LINC00518 in CC tissues and cell lines were determined by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), and its clinical significance was assessed by statistical analysis. Cell apoptosis was determined by flow cytometry. The cell proliferation was evaluated by MTT assay and colony forming assay, and the migration and invasion were evaluated by wound healing assays and transwell assay. Western blot was used to detect the expression of relative proteins, including EMT markers and the JAK/STAT3 signaling markers.
RESULTS: We found that LINC00518 was upregulated in CC tissues and associated with International Federation of Gynaecology and Obstetrics (FIGO) stage, lymph node metastasis, depth of cervical invasion and poor survival of CC patients. Univariate and multivariate Cox regression analysis showed that LINC00518 played a significant role of independent prognostic markers in overall survival rates. Furthermore, knocking down LINC00518 expression significantly suppressed CC cell proliferation, migration and invasion, and induced apoptosis in vitro. Mechanistically, the downregulation of LINC00518 suppressed JAK/STAT3 activation and subsequently decreased N-Cadherin and Vimentin.
CONCLUSIONS: The present work first suggests that LINC00518 acts as an oncogene in CC via regulation of the JAK/STAT3 signaling pathway. In the future, LINC00518 may serve as a predictive biomarker and potential therapeutic target for CC patients.Free PDF Download
To cite this article
D.-W. Wang, D. You, J. Dong, T.-F. Liu
Knockdown of long non-coding RNA LINC00518 inhibits cervical cancer proliferation and metastasis by modulating JAK/STAT3 signaling
Eur Rev Med Pharmacol Sci
Vol. 23 - N. 2